Statera BioPharma
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$3.21K
-0.0
-0.28
$2.68M
46
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is headquartered in Fort Collins, Colorado and currently employs 46 full-time employees. The company went IPO on 2006-07-21. Through its developmental Advanced Immunomodulating Multi-Component System (AIMS) platform, it has advanced several late-stage developmental product candidates. AIMS allows it to integrate multiple factors that define a superior composition, including key pharmacokinetic-pharmacodynamic relationships, potency, and selectivity. The firm has a platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and Entalasta. The company has clinical and preclinical programs for Crohn’s disease (STAT-201), hematology (Entolimod) and inflammation (STAT-300) in addition to potential expansion into fibromyalgia and multiple sclerosis.
emptyResult
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is headquartered in Fort Collins, Colorado and currently employs 46 full-time employees. The company went IPO on 2006-07-21. Through its developmental Advanced Immunomodulating Multi-Component System (AIMS) platform, it has advanced several late-stage developmental product candidates. AIMS allows it to integrate multiple factors that define a superior composition, including key pharmacokinetic-pharmacodynamic relationships, potency, and selectivity. The firm has a platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and Entalasta. The company has clinical and preclinical programs for Crohn’s disease (STAT-201), hematology (Entolimod) and inflammation (STAT-300) in addition to potential expansion into fibromyalgia and multiple sclerosis.